Trial Profile
An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Murepavadin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Polyphor
- 16 Jul 2018 Results published in the Antimicrobial Agents and Chemotherapy
- 16 Jun 2016 Number of treatments arms changed from 5 to 6.
- 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases